论文部分内容阅读
目的观察α-SMA+的肿瘤相关成纤维细胞(cancer-associated fibroblasts,CAFs)与肺腺癌患者临床病理特征及肿瘤浸润免疫细胞的相关性,为认识CAFs在肺腺癌发生中的作用提供依据,并将为临床肺腺癌的诊疗提供新思路。方法收集56例临床手术切除且病理诊断为原发肺腺癌的肿瘤组织标本,收集患者一般情况及临床病理学特征等资料。免疫组织化学染色方法检测肺腺癌患者肿瘤标本中α-SMA、CD4、CD8及CD33的表达情况,病理学方法计数间质细胞及α-SMA阳性的CAFs,统计学方法分析CAFs比例与患者临床病理特征及肿瘤浸润免疫细胞的相关性。结果α-SMA+CAFs比例与患者吸烟及肿瘤TNM(tumor,node,metastasis)分期呈正相关(P<0.05),与肿瘤分化程度呈负相关(P<0.05),但与患者年龄、性别及肿瘤浸润CD4+T细胞、CD8+T细胞及MDSCs(myeloid-derived suppressor cells,MDSCs)的数量无明显相关。结论α-SMA+CAFs与肺腺癌的发生发展密切相关,其与肿瘤临床分期及分化程度的相关性提示其在肺腺癌的发生发展中起促进作用,对其深入机制的阐明将有助于完善肺腺癌的发生机制并将为其治疗提供新思路。
Objective To observe the relationship between the expression of α-SMA + -cancerous fibroblasts (CAFs) and the clinicopathological features and tumor infiltrating immune cells in patients with lung adenocarcinoma, so as to provide basis for understanding the role of CAFs in the development of lung adenocarcinoma, And will provide new ideas for clinical diagnosis and treatment of lung adenocarcinoma. Methods Totally 56 cases of primary lung adenocarcinoma resected and pathologically diagnosed were collected and the general situation and clinicopathological features were collected. The expression of α-SMA, CD4, CD8 and CD33 in tumor samples from patients with lung adenocarcinoma was detected by immunohistochemical staining. The number of interstitial cells and α-SMA positive CAFs were counted by pathology. The ratio of CAFs to the clinical data Pathological features and tumor infiltrating immune cells correlation. Results The proportion of α-SMA + CAFs was positively correlated with smoking and TNM stage (P <0.05), but negatively correlated with tumor differentiation (P <0.05), but not with age, sex and tumor No significant correlation was found between the numbers of infiltrating CD4 + T cells, CD8 + T cells and MDSCs (MDSCs). Conclusions α-SMA + CAFs are closely related to the occurrence and development of lung adenocarcinoma. The correlation between α-SMA + CAFs and the clinical stage and differentiation of tumors suggests that α-SMA + CAFs may play an important role in the development of lung adenocarcinoma. To improve the mechanism of lung adenocarcinoma and provide new ideas for its treatment.